FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID ...Middle East

LEXINGTON, Mass., July 6, 2023 /PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, today announced...

Hence then, the article about fda removes partial clinical hold on takeaim leukemia study rp2d established at 300 mg bid was published today ( Thursday 06/07/2023 - 03:05 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID )

Also on site :

• Thousands rally in Serbia as students continue fight against corruption
• Today’s NYT ‘Strands’ Hints, Spangram and Answers for Sunday, January 18, 2026
• 'SNL' Parodies 'Heated Rivalry' With Harry Potter Characters — And a Genius Cameo